Sorafenib tosylate, Ribavirn and Sofosbuvir combination therapy for HCV virus infected patients with decompensated liver cancer.
Saved in:
| Title: | Sorafenib tosylate, Ribavirn and Sofosbuvir combination therapy for HCV virus infected patients with decompensated liver cancer. |
|---|---|
| Authors: | Munir B; Department of Biochemistry, Government College University, Faisalabad, Pakistan., Ahmed B; Department of Biochemistry, Government College University, Faisalabad, Pakistan., Kiran S; Department of Applied Chemistry, Government College University, Faisalabad, Pakistan., Jalal F; Department of Zoology, Government College University, Faisalabad, Pakistan., Zahoor MK; Department of Zoology, Government College University, Faisalabad, Pakistan., Shehzadi S; Department of Biochemistry, Government College University, Faisalabad, Pakistan., Oranab S; Department of Biochemistry, Government College University, Faisalabad, Pakistan., Kamran SK; Department of Physiology, Government College University, Faisalabad, Pakistan., Ghaffar A; Department of Biochemistry, Government College University, Faisalabad, Pakistan. |
| Source: | Pakistan journal of pharmaceutical sciences [Pak J Pharm Sci] 2017 Nov; Vol. 30 (6(Supplementary)), pp. 2383-2387. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Faculty of Pharmacy, University of Karachi Country of Publication: Pakistan NLM ID: 9426356 Publication Model: Print Cited Medium: Print ISSN: 1011-601X (Print) Linking ISSN: 1011601X NLM ISO Abbreviation: Pak J Pharm Sci Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
